EGFR and hepatocellular carcinoma: Tremelimumab is a monoclonal antibody approved for HCC and NSCLC, used with durvalumab and chemotherapy for unresectable cases.382 Tremelimumab is indicated as a first-line treatment for metastatic NSCLC in patients who do not have sensitizing EGFR mutations or ALK-positive mutations.